과민성대장증후군 치료 시장 규모, 점유율, 동향 및 예측 : 유형, 제품 유형, 유통 채널, 지역별(2026-2034년)

The global irritable bowel syndrome treatment market size was valued at USD 3.11 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.12 Billion by 2034, exhibiting a CAGR of 7.5% from 2026-2034. North America currently dominates the market, holding a market share of 41.2% in 2025. The region benefits from a well-established healthcare infrastructure, high awareness levels regarding gastrointestinal disorders, widespread adoption of advanced therapeutic options, and favorable reimbursement policies that support patient access to innovative treatments, all contributing to the irritable bowel syndrome treatment market share.

The escalating global prevalence of irritable bowel syndrome, driven by changing dietary patterns, sedentary lifestyles, and increasing stress levels among the population, is propelling the demand for effective therapeutic interventions across the globe. Furthermore, the expanding geriatric population, which demonstrates heightened susceptibility to gastrointestinal disorders, is catalyzing the need for comprehensive treatment solutions. The growing awareness regarding gut health and the gut-brain axis connection is encouraging individuals to seek medical attention for digestive issues. Additionally, advancements in diagnostic modalities are enabling earlier detection of IBS subtypes, which facilitates appropriate treatment selection. The rising adoption of personalized medicine approaches tailored to individual patient characteristics is enhancing treatment efficacy. Moreover, the expanding healthcare expenditure in both developed and developing economies is improving access to pharmaceutical interventions for IBS management.

The United States has become a key region in the treatment of irritable bowel syndrome due to a number of factors. First, the country has a good healthcare infrastructure that allows patients to access diagnostic and treatment options for gastrointestinal disorders. According to a survey conducted in 2024, involving almost 89,000 people, about 6.1% of the United States population is suffering from irritable bowel syndrome, as identified by Rome IV criteria. This shows that there is a high demand for treatment of the condition. The presence of key pharmaceutical companies that are investing in research and development of new treatment options for irritable bowel syndrome is a major factor that is propelling the growth of the treatment market. In addition, the awareness of doctors regarding the availability of treatment options is a key factor that is propelling the use of new treatment options. The availability of prescription drugs through a well-established pharmacy network is a key factor that is propelling the accessibility of treatment options.

Rising Focus on Microbiome-Based Therapies

The rising interest in researching gut microbiome modulation is revolutionizing the treatment of irritable bowel syndrome. Researchers have increasingly sought to understand the role of an imbalance in intestinal flora in the pathophysiology of IBS. This understanding has resulted in the development of unique probiotics and prebiotics. Fecal transplantation techniques have been recognized as effective treatments for IBS. The pharmaceutical industry is investing heavily in the development of oral treatments aimed at correcting imbalances in the intestinal flora. For example, in March 2025, EnteroBiotix reported positive results in phase 2a trial results for its next-generation full-spectrum microbiome treatment, EBX-102-02. This treatment demonstrated clinically significant effects in various aspects of IBS-C symptoms. Advances in understanding the interrelation between the gut and the brain have allowed for the development of treatments for IBS symptoms. This understanding of IBS and its treatment mechanisms has seen institutions and biotech companies collaborate in the development of unique treatments for IBS.

Advancement in Personalized Medicine Approaches

This shift in personalized approaches in medical strategies is altering the IBS management paradigms, with healthcare professionals increasingly personalizing treatment regimens based on individual patient characteristics. Pharmacogenomic testing helps healthcare professionals predict the outcome of medication regimens in patients, thereby optimizing therapeutic outcomes while preventing adverse reactions to drugs. Genetic profiling and microbiome testing have aided in the identification of patient groups that exhibit increased susceptibility to treatment regimens. For example, in February 2025, researchers from Michigan Medicine and Cleveland Clinic developed a new personalized approach to IBS treatment based on blood test panels to identify and remove trigger foods in patients with irritable bowel syndrome. This patient-centric approach is gaining popularity, as it helps in addressing the heterogeneity of irritable bowel syndrome manifestations in patients. The use of digital health tools, which use artificial intelligence algorithms, is helping personalize treatment regimens, thereby supporting irritable bowel syndrome treatment market growth.

Integration of Digital Health Solutions

The integration of digital therapeutics and telemedicine tools is significantly changing the way IBS patients receive treatment, making the patient engagement and adherence to treatment more effective for global healthcare systems. Mobile apps for symptom management and diet control are empowering patients to be more engaged and participatory in the management of their condition. Cognitive behavioral therapy, when conducted through digital media, has shown promising outcomes for the management of the psychological aspects of the manifestation of irritable bowel syndrome. Integration of telehealth tools has also provided the opportunity for the remote management of patients, especially for those living in underserved areas, which has improved the outlook for the irritable bowel syndrome treatment market. Integration of virtual reality tools for stress management and gut-directed hypnotherapy has provided a new avenue for the management of patients presenting with complicated forms of the condition, requiring a multimodal therapeutic approach.

Analysis by Type:

• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS

IBS with diarrhea (IBS-D) holds 43.5% of the market share. The segment dominance is attributed to the substantial patient population experiencing diarrhea-predominant symptoms and the availability of targeted therapeutic options including rifaximin and eluxadoline. The chronic nature of IBS-D necessitates ongoing management, driving sustained demand for effective medications that address both abdominal pain and altered bowel habits. According to the American Gastroenterological Association survey conducted between October and November 2024, patients with IBS reported missing approximately 3.6 work or school days per month due to gastrointestinal symptoms, highlighting the significant burden of the condition. The increasing diagnosis rates facilitated by improved awareness among healthcare providers are expanding the identified patient pool. Furthermore, the growing emphasis on patient education initiatives encourages individuals to seek appropriate medical attention for persistent symptoms. The development of innovative therapies targeting specific pathophysiological mechanisms underlying IBS-D presentations is enhancing the irritable bowel syndrome treatment market forecast, providing patients with expanded treatment alternatives.

Analysis by Product:

• Rifaximin
• Eluxadoline
• Lubiprostone
• Linaclotide
• Others

Rifaximin leads the market with a share of 36.9%. The dominance of rifaximin is attributed to its established efficacy as a non-systemic antibiotic that modulates gut microbiota while demonstrating minimal systemic absorption and favorable tolerability profiles. The medication has gained widespread acceptance among gastroenterologists for managing diarrhea-predominant IBS symptoms, supported by robust clinical evidence demonstrating significant improvements in global IBS symptoms. According to regulatory filings in January 2025, the FDA granted tentative approval to generic versions of rifaximin 550 mg tablets, indicating continued strong market interest in this therapeutic category. The convenience of oral administration and the ability to provide repeat treatment courses for symptom recurrence have enhanced patient acceptance. The expanding indications for rifaximin across various gastrointestinal conditions are strengthening its market position. Additionally, strategic partnerships between pharmaceutical companies are enhancing distribution capabilities and market penetration across diverse geographic regions, supporting sustained segment growth.

Analysis by Distribution Channel:

• Hospitals Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores

Drug stores and retail pharmacies dominate the market, with a share of 52.4%. The dominance of this segment is attributed to the widespread accessibility and convenience offered by retail pharmacy networks that enable patients to obtain prescription and over-the-counter medications efficiently. The established infrastructure of retail pharmacies across urban and suburban areas facilitates consistent medication availability for chronic condition management. Moreover, retail pharmacies generated substantial revenue from IBS treatments, with projections indicating continued expansion driven by increasing product availability. The personalized consultation services provided by pharmacists enhance patient understanding of treatment regimens and improve adherence rates. The expansion of chain pharmacy networks and the integration of digital prescription services are streamlining the medication dispensing process. Additionally, the availability of pharmacist-led counseling programs educates patients on lifestyle modifications that complement pharmacological interventions for comprehensive IBS management.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for 41.2% of the share, enjoys the leading position in the market. The regional dominance is supported by the high prevalence of irritable bowel syndrome affecting approximately 25 to 45 million people in the United States alone, combined with well-established healthcare infrastructure and favorable reimbursement frameworks. According to the American Gastroenterological Association survey in 2024, approximately 81% of healthcare providers acknowledged that social media has helped increase public awareness of IBS. The presence of leading pharmaceutical companies investing in innovative therapeutic development strengthens the regional market position. Advanced diagnostic capabilities enable accurate subtype classification, facilitating appropriate treatment selection. The high adoption rates of prescription medications including Linzess and Xifaxan demonstrate strong physician confidence in available therapeutic options. Additionally, supportive government policies and expanding insurance coverage are enhancing patient access to comprehensive gastrointestinal care services across the region.

UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The United States dominates the North American irritable bowel syndrome treatment market, driven by the substantial patient population and advanced healthcare delivery systems. The country benefits from a robust pharmaceutical industry that continuously invests in research and development activities for novel therapeutic interventions targeting various IBS subtypes. According to the American Gastroenterological Association IBS in America survey released in August 2025, IBS symptoms interfere with patients' productivity at work or school for nearly 11 days per month on average, underscoring the significant disease burden. The widespread availability of FDA-approved medications through established pharmacy networks ensures consistent patient access to therapeutic options. The increasing adoption of digital health solutions including telemedicine consultations and symptom-tracking applications is enhancing patient engagement and treatment adherence. Healthcare provider awareness regarding treatment advances enables informed therapeutic decision-making. The favorable reimbursement landscape supports patient access to both established and innovative treatment options across diverse insurance frameworks.

EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

Europe represents a significant market for irritable bowel syndrome treatment, supported by established healthcare systems and increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. The region benefits from favorable regulatory frameworks that facilitate the approval and market entry of innovative therapeutic options. In 2025, Alfasigma received European Medicines Agency approval for a new formulation of rifaximin specifically indicated for treating diarrhea-predominant irritable bowel syndrome in adults. The presence of well-developed healthcare infrastructure across major economies including Germany, France, and the United Kingdom ensures comprehensive patient access to diagnostic and treatment services. Growing emphasis on patient education initiatives is encouraging individuals to seek appropriate medical attention for persistent symptoms. The expanding adoption of combination therapy approaches integrating pharmacological interventions with dietary modifications and behavioral therapies is enhancing overall treatment outcomes across the region.

ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The Asia-Pacific region demonstrates rapid growth potential in the irritable bowel syndrome treatment market, driven by rising awareness, improving healthcare infrastructure, and increasing disposable incomes across major economies. According to statistical analysis performed using Open MetaAnalyst and published in 2025, reviewing studies from 2006 to 2024, the global prevalence of IBS is approximately 14.1%, with significant variations observed across Asian countries. India has emerged as a major contributor in Asia-Pacific, supported by increased diagnosis rates, changing dietary patterns, and growing healthcare consumer engagement. The expanding presence of pharmaceutical companies and the launch of innovative products are enhancing treatment accessibility across the region.

LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

Latin America presents growing opportunities in the irritable bowel syndrome treatment market, supported by increasing healthcare expenditure and expanding access to pharmaceutical interventions. The region is witnessing improved awareness regarding gastrointestinal disorders as healthcare providers emphasize patient education initiatives. According to industry reports in 2024, major pharmaceutical companies are expanding their distribution networks across Brazil and Mexico to enhance treatment accessibility. The developing healthcare infrastructure is facilitating improved diagnostic capabilities and treatment delivery.

MIDDLE EAST AND AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

The Middle East and Africa region represents an emerging market for irritable bowel syndrome treatment, driven by increasing healthcare investments and growing awareness regarding digestive health disorders. According to industry analysis in 2025, the region is witnessing gradual expansion in pharmaceutical distribution networks and healthcare facility development. Government initiatives aimed at strengthening healthcare delivery systems are improving patient access to diagnostic and treatment services. The expanding presence of multinational pharmaceutical companies is enhancing the availability of innovative therapeutic options across major urban centers.

Competitive Landscape:

The irritable bowel syndrome treatment market exhibits a moderately concentrated competitive landscape, with established pharmaceutical companies leveraging strong brand presence, clinical expertise, and robust distribution networks to maintain market positions. Key players are focusing on strategic partnerships, licensing agreements, and research collaborations to accelerate the development of innovative therapeutic options. The increasing emphasis on personalized medicine approaches is driving investment in diagnostic tools that facilitate patient stratification and treatment optimization. Companies are expanding their product portfolios through acquisitions of biotechnology firms specializing in gastrointestinal therapies. The growing adoption of digital health platforms for patient engagement and remote monitoring represents an emerging competitive differentiator. Manufacturing capacity expansions are enabling companies to meet rising global demand for established treatment options. Furthermore, market participants are enhancing their geographic presence through strategic distribution partnerships across emerging economies.

The report provides a comprehensive analysis of the competitive landscape in the irritable bowel syndrome treatment market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Allergan plc (AbbVie Inc.)
• Ardelyx Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bausch Health Companies Inc.
• GlaxoSmithKline Plc
• Novartis AG
• Sebela Pharmaceuticals Inc.
• Synthetic Biologics Inc.
• Takeda Pharmaceutical Company Limited

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the irritable bowel syndrome treatment market?

2. What is the future outlook of the irritable bowel syndrome treatment market?

3. What are the key factors driving the irritable bowel syndrome treatment market?

4. Which region accounts for the largest irritable bowel syndrome treatment market share?

5. Which are the leading companies in the global irritable bowel syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Irritable Bowel Syndrome Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 IBS with Diarrhea (IBS-D)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 IBS with Constipation (IBS-C)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Mixed IBS
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Product

• 7.1 Rifaximin
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Eluxadoline
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Lubiprostone
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Linaclotide
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospitals Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Drug Stores and Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Allergan plc (AbbVie Inc.)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Ardelyx Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Astellas Pharma Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 AstraZeneca plc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Bausch Health Companies Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 GlaxoSmithKline Plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Novartis AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Sebela Pharmaceuticals Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Synthetic Biologics Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Takeda Pharmaceutical Company Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis